Paraganglioma Clinical Trials Near Me
As of October 12, 2026, 38 Paraganglioma clinical trials are recruiting or about to open (29 recruiting now, 9 opening soon). 17 of them have at least 1 open site in the United States, across 22 states. Enter your ZIP code to see which are closest to you.
Also on Trial Friend:Paraganglioma pageMatch Me
All 29 Paraganglioma trials and their US sites
Enter your ZIP code above to sort them by how far their nearest open site is from you.
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsMayo Clinic, Jacksonville, Florida; Biogenix Molecular, Miami, Florida; The University of Chicago, Chicago, Illinois and 16 more sitesRecruitingPhase 1/2Ages 18 to 90Run by Perspective Therapeutics
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California; Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois; Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville, Illinois and 7 more sitesRecruitingPhase 2Ages 12+Run by Merck Sharp & Dohme LLC
- Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaUCLA, Los Angeles, California; Stanford, Palo Alto, California; U of Colorado, Aurora, Colorado and 6 more sitesRecruitingPhase 2Ages 18+Run by Jazz Pharmaceuticals
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsCity of Hope, Duarte, California; UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California; Stanford Cancer Institute, Stanford, CaliforniaRecruitingPhase 1Ages 18 to 75Run by Anusha Kalbasi
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersNational Institutes of Health Clinical Center, Bethesda, MarylandRecruitingPhase 1Ages 18 to 120Run by National Cancer Institute (NCI)
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionNational Institutes of Health Clinical Center, Bethesda, MarylandRecruitingPhase 2Ages 18 to 120Run by National Cancer Institute (NCI)
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.Weill Cornell Medicine, New York, New YorkRecruitingPhase 4Ages 18 to 100Run by Weill Medical College of Cornell University
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsNational Institutes of Health Clinical Center, Bethesda, MarylandRecruitingPhase 1Ages 18 to 120Run by National Cancer Institute (NCI)
- Familial Investigations of Childhood Cancer PredispositionSt. Jude Children's Research Hospital, Memphis, TennesseeRecruitingRun by St. Jude Children's Research Hospital
- Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated ConditionsUniversity of Texas Health Science Center, San Antonio, TexasRecruitingRun by The University of Texas Health Science Center at San Antonio
- In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and ParagangliomaAbramson Cancer Center of the University of Pennsylvania, Philadelphia, PennsylvaniaRecruitingEarly Phase 1Ages 18+Run by Heather Wachtel
- Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaNational Institutes of Health Clinical Center, Bethesda, MarylandRecruitingPhase 2Ages 18 to 100Run by National Cancer Institute (NCI)
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand TherapyNational Institutes of Health Clinical Center, Bethesda, MarylandRecruitingPhase 1/2Ages 18 to 120Run by National Cancer Institute (NCI)
- Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemPenn Medicine, Philadelphia, PennsylvaniaRecruitingAges 18+Run by University of Pennsylvania
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCNo open US site listed yetRecruitingPhase 2Ages 18+Run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorNo open US site listed yetRecruitingEarly Phase 1Ages 1 to 80Run by Peking Union Medical College Hospital
- Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and ParagangliomaNo open US site listed yetRecruitingAges 18 to 80Run by Peking Union Medical College Hospital
- An Experimental Study of Belzutifan Impact on Catecholamine MetabolismNo open US site listed yetRecruitingPhase 2Run by Cambridge University Hospitals NHS Foundation Trust
- An International Study on Pediatric Patients With Rare Tumors.No open US site listed yetRecruitingAges 0 to 18Run by Azienda Ospedaliera di Padova
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaNo open US site listed yetRecruitingAges 6 Months+Run by Nanjing First Hospital, Nanjing Medical University
New trials, status changes and new sites, straight from ClinicalTrials.gov. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Paraganglioma. Turn any of these off from the link in every email.
Where Paraganglioma trials are recruiting in the US
The US cities with the most Paraganglioma trials recruiting are Bethesda, Maryland (6), Philadelphia, Pennsylvania (4), Los Angeles, California (3), Ann Arbor, Michigan (2) and Baltimore, Maryland (2), counting trials with at least 1 open site in each city.
Hospitals that run trials for a rare condition often see more people with it than most clinics do, so this list can also help you find doctors who know Paraganglioma, even if no trial fits you.
- National Institutes of Health Clinical Center
- National Institutes of Health ( Site 0125)
- Abramson Cancer Center of the University of Pennsylvania
- PENN
- Penn Medicine
- and 1 more
- Cedars-Sinai Medical Center ( Site 0110)
- UCLA
- UCLA / Jonsson Comprehensive Cancer Center
- U of Michigan
- University of Michigan ( Site 0126)
- Johns Hopkins
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108)
- Brigham and Women's Hospital (BWH)
- Dana-Farber Cancer Institute
- Massachusetts General Hospital ( Site 0111)
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130)
- The University of Chicago
- MD Anderson Cancer Center
- University of Texas MD Anderson Cancer Center ( Site 0112)
States with at least 1 open site: California, Colorado, Florida, Illinois, Iowa, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin.
Questions about finding a Paraganglioma trial near you
Are there Paraganglioma clinical trials near me?
As of October 12, 2026, 38 Paraganglioma clinical trials are recruiting or about to open (29 recruiting now, 9 opening soon). 17 of them have at least 1 open site in the United States, across 22 states. Enter your ZIP code on this page to rank every one of them by the distance to its closest open site, with the sites shown on a map.
Which states have Paraganglioma clinical trial sites?
As of October 12, 2026, recruiting Paraganglioma trials list open sites in 22 states. The US cities with the most Paraganglioma trials recruiting are Bethesda, Maryland (6), Philadelphia, Pennsylvania (4), Los Angeles, California (3), Ann Arbor, Michigan (2) and Baltimore, Maryland (2), counting trials with at least 1 open site in each city.
What if there is no Paraganglioma trial near me?
Some trials pay for or reimburse travel and lodging, and a few send staff or use local labs so fewer visits happen at the study site, so ask the study contact before ruling a trial out. You can also sign up on this page to get an email when a Paraganglioma trial opens a new site or changes status.
How is the distance to a trial site measured?
Distances are straight-line miles from the center of your ZIP code to each study site's listed location, not driving distance. Your browser looks up the ZIP code's coordinates with a free map service, Zippopotam.us, and the ZIP code is never sent to or stored by Trial Friend.
FDA-approved for Paraganglioma: Welireg (belzutifan).
Source: ClinicalTrials.gov, trials with status Recruiting or Not yet recruiting. Refreshed every 6 hours; counts as of October 12, 2026. Sites that ClinicalTrials.gov lists as closed or withdrawn are left out.